The Pharmacodynamics of Cannabinoid-Caffeine Combinations

NCT05478863 EARLY_PHASE1 COMPLETED

Cannabis and caffeine are two of the most commonly consumed psychoactive substances in the world, with many consumers reporting positive impacts on energy, alertness, and focus. Preliminary evidence has suggested that cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, may mitigate the negative side effects of caffeine (e.g., feeling jittery) without impacting positive or desired effects. CBD also shows potential in reducing undesirable acute effects (e.g., anxiety) of delta-9-tetrahydrocannabinol (THC), the primary intoxicating cannabinoid found in cannabis. Despite these promising findings, little is known about the potential effects of THC, caffeine, and CBD in combination. This double-blind, randomized, placebo-controlled, within-subject crossover study will assess the effects of combinations of THC, CBD, and caffeine (i.e., THC only; THC + caffeine; THC + CBD + caffeine) on subjective energy, arousal, and cognitive performance.

Details

Lead sponsor	Johns Hopkins University
Phase	EARLY_PHASE1
Status	COMPLETED
Enrolment	20
Start date	Fri Jan 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Oct 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Behavioral Pharmacology of Cannabinoids

Interventions

• Oral Placebo
• Oral THC
• Oral CBD
• Oral Caffeine

Countries

United States